Linagliptin

Linagliptin is a medication that belongs to the class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. It is primarily used to treat type 2 diabetes mellitus by helping to improve blood sugar control. The drug works by inhibiting the enzyme DPP-4, which helps to increase levels of incretin hormones, leading to improved insulin secretion and reduced glucagon release.

Mechanism of Action

• Linagliptin exerts its effects by inhibiting the activity of the enzyme dipeptidyl peptidase-4 (DPP-4). This inhibition prevents the breakdown of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By increasing the levels of these incretin hormones, Linagliptin enhances insulin secretion in response to high blood glucose levels and reduces glucagon release, thereby lowering blood glucose levels.

Indications

• It is commonly prescribed for the management of type 2 diabetes mellitus, particularly in patients who require additional glycemic control beyond diet and exercise. In some cases, it may also be used off-label for other metabolic conditions under close medical supervision.